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LETTER TO THE EDITOR
Sensitivity and specificity of
SkinVision are likely to have been
overestimated
Editor
Udrea et al.1 reported 95.1% sensitivity and 78.3% specificity
using the SkinVision app for risk assessment of skin lesions.
These are likely to be overestimated due to the nature of the
study design and flaws in sampling.
The study design, where inclusion of those with and without
disease is undertaken separately, is known as a diagnostic case–
control study or a two-gate design.2 These studies have been
shown to overestimate both sensitivity and specificity across
many clinical applications compared to the ideal design, where
all using the test as intended are recruited to a study prior to
ascertaining disease status.3
The risk of bias in this study is further increased by the
method of lesion selection. The app is intended for use by
laypersons to self-assess skin lesions; thus, its accuracy should be
assessed in this context. Three previous studies of SkinVision
have been entirely based on clinically selected cohorts.4–6 Udrea
et al. did use some app users’ data for evaluation; however, these
data are mixed with clinical cohorts, and the app users have been
selected in a way that is almost certain to have introduced bias.
The sensitivity of the app was evaluated in two cohorts of clin-
ically investigated patients combined with a cohort of app users.
The clinical cohorts are from previous studies5,6 including 48
malignant melanomas (40 from Munich,5 8 from Eindhoven6)
with 147 other malignant and premalignant lesions (all from
Eindhoven: 107 basal and 8 squamous cell carcinomas; 18 actinic
keratosis; 14 Bowen’s Disease). Although inclusion of secondary
care cohorts ensures histological verification, these patients have
gone through several selection steps (choosing to present to pri-
mary care, referral from primary care, excision decision in sec-
ondary care) and are thus unlikely to be representative of typical
app users, and possibly reflect more clearly defined cases than
the early skin cancer that the app aims to detect.
However, it is the selection of data collected from app users
which is the more serious flaw. All app users had used a previous
SkinVision app, with the image checked by a dermatologist – a
senior dermatologist for high-risk images and a junior dermatol-
ogist for low-risk images. Users with high-risk results were
invited to provide follow-up data, resulting in the inclusion of 90
high-risk-rated melanomas. Malignant lesions previously missed
by the app (estimated as 20% in the Eindhoven cohort6) and the
check by junior dermatologists could not have been included
and are likely to be the more difficult to diagnose cases. The pro-
portion of those invited to follow-up who provided histology
results (338 of 48 547 – 0.7%) is very small, with substantial fur-
ther potential for selection bias. Verification of the 6000 benign
lesions was based on the junior dermatologist’s assessment of a
single image taken by the app with no histology or follow-up
data, which is suboptimal. Recruitment of benign lesions seems
to have been restricted to those judged as low or medium risk by
the previous SkinVision app and clinical assessment, and the
false-positive cases from that app (22% of benign lesions in the
Eindhoven data6) will have been automatically excluded, and are
likely to have been more difficult to diagnose. These flaws make
overestimation of both sensitivity and specificity highly likely.
Whilst skin cancer diagnosis apps might make valuable con-
tributions, screening applications for public use can easily do
harm through missing skin cancer cases and from over-investi-
gation of false positives. It is essential that appropriate studies
are done before recommendations are made to widely dissemi-
nate technologies, as is happening with SkinVision.7 We have
recently reviewed all evidence of the accuracy of skin diagnosis
apps which use inbuilt algorithms and failed to find any exam-
ples of well-done studies.8 Our review contains constructive
guidance for investigators to minimize bias and increase external
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